Pharmaceutical Manufacturing and Processing Equipment Market Size, Share, Growth, and Industry Analysis, By Types (Agitators, Blowers, Coaters, Dryers, Granulators, Metal Detectors, Sifters, Others) , Applications (Tablets, Capsules, Injectable, Sprays, Powders, Other) and Regional Insights and Forecast to 2033

Pharmaceutical Manufacturing and Processing Equipment Market Size

The global Pharmaceutical Manufacturing and Processing Equipment Market Size was valued at USD 63,464.82 million in 2024 and is projected to reach USD 67,520.22 million in 2025, expanding to USD 110,825.67 million by 2033. The market is expected to grow at a CAGR of 6.39% from 2025 to 2033, driven by rising pharmaceutical production, increasing investment in biopharmaceuticals, and advancements in automation and AI-driven manufacturing.

The US Pharmaceutical Manufacturing and Processing Equipment Market Size is growing rapidly due to the increasing demand for high-quality drug production, strong government support for domestic pharmaceutical manufacturing, and the rapid adoption of smart manufacturing technologies. The expansion of biopharma and vaccine production facilities is further fueling market growth.

Key Findings 

• Automation Adoption: Over 64% of pharmaceutical companies are investing in automated systems to improve efficiency and production accuracy in the manufacturing process. Automation helps reduce human error and enhances operational speed in drug production.
• Increase in Aseptic Processing Equipment: The demand for aseptic processing equipment has increased by 39% due to the growing production of biologics and vaccines, particularly in sterile environments.
• Modular Systems Investment: More than 47% of contract manufacturers are focusing on modular systems to ensure flexibility and scalability in production, which is crucial for high-volume pharmaceutical production.
• Single-Use Systems:
  39% of pharmaceutical manufacturing companies are now utilizing single-use systems, driven by the need to reduce contamination risks and improve production efficiency in biologics manufacturing.
• Energy-Efficient Equipment:
   The demand for energy-efficient pharmaceutical manufacturing equipment has grown by 33%, as pharmaceutical manufacturers are increasingly focusing on sustainability and reducing their carbon footprint.
• Digitalization and Smart Technology: 61% of new product releases in the market now include cloud-based analytics or IoT integration, signaling a shift towards smarter, data-driven manufacturing systems that allow for real-time monitoring and predictive maintenance.
• Investment in Biologics and Biopharma: In Asia-Pacific, investments in biologics production equipment have surged by 44%, indicating the region's growing importance in the global pharmaceutical manufacturing ecosystem.
• Increase in Product Development: 41% of new product developments focus on improving manufacturing capabilities for biologics and vaccines, with innovations in granulation, coating, and drying technologies to improve efficiency.
• Regional Growth in Manufacturing: 52% of global pharmaceutical manufacturers have expanded or upgraded their manufacturing facilities in North America, while 43% of growth is happening in Asia-Pacific due to growing demand for generics and local production in emerging markets.
• Regulatory Compliance: Over 68% of pharmaceutical manufacturers are upgrading their equipment to ensure compliance with stricter regulatory standards, such as cGMP and FDA guidelines.



Request a Free sample    to learn more about this report.

The Pharmaceutical Manufacturing and Processing Equipment market is witnessing a surge in demand due to the rapid expansion of pharmaceutical production capacity across global regions. Over 65% of pharma manufacturers are adopting automated equipment to meet increasing drug output requirements. Around 72% of facilities are upgrading their existing equipment to comply with evolving regulatory norms. The demand for sterile processing equipment has risen by over 58% due to the growth of biologics and vaccines. Meanwhile, over 60% of emerging pharmaceutical companies in Asia-Pacific are investing in modern machinery to reduce production downtime and boost operational efficiency.

Pharmaceutical Manufacturing and Processing Equipment Market Trends 

The Pharmaceutical Manufacturing and Processing Equipment market is evolving rapidly, influenced by high-tech trends and regulatory shifts. Currently, more than 68% of pharma manufacturers are integrating automation into their production lines. Robotics usage in pharma manufacturing has increased by 47% in the past five years. There is also a growing inclination toward continuous manufacturing systems, which have seen a 55% adoption rate due to their efficiency and real-time control features.

Single-use systems now account for over 62% of new biologic manufacturing setups, helping reduce cross-contamination and setup time. Cleanroom equipment demand has risen by 49%, especially in injectable and sterile formulation segments. Additionally, digital twin technology is gaining traction, with a 33% increase in implementation for predictive maintenance and process optimization.

Modular equipment systems, which allow rapid line reconfiguration, are now preferred by 57% of CDMOs and CMOs. Industry 4.0 technologies like AI and IoT have seen a 41% increase in adoption across pharma production units. Furthermore, over 51% of manufacturers are transitioning to eco-efficient systems to reduce carbon footprint and energy consumption. These trends are reshaping the global pharmaceutical manufacturing and processing equipment market, pushing manufacturers toward innovation and smarter production.

Pharmaceutical Manufacturing and Processing Equipment Market Dynamics

Dynamic forces influencing the Pharmaceutical Manufacturing and Processing Equipment market include growing global medicine consumption, changing healthcare demands, and evolving drug manufacturing standards. Over 66% of pharmaceutical companies are now outsourcing manufacturing operations to specialized facilities, increasing demand for modular and scalable equipment. Regulatory requirements are driving 73% of manufacturers to adopt advanced compliance-ready systems. The growth of complex drug formulations has resulted in 59% of pharma firms investing in high-precision processing technologies. Meanwhile, rising healthcare investments in emerging markets are prompting 62% of domestic players to upgrade infrastructure with new processing machinery. These combined factors are accelerating market growth and equipment innovation.

DRIVER

" Rising Demand for Pharmaceuticals"

The pharmaceutical manufacturing and processing equipment market is largely driven by the increasing global demand for pharmaceutical products. Over 69% of the world’s population now has access to essential medicines, leading to a significant spike in drug production. More than 75% of pharmaceutical companies have expanded their production capacity over the past five years. The global population over the age of 60 is expected to reach 22% by 2030, further increasing chronic disease-related drug demand. Vaccine manufacturing alone has triggered a 63% rise in sterile equipment deployment. This rising pharmaceutical need is directly translating into greater demand for high-output and precise manufacturing equipment.

RESTRAINT

"Demand for Refurbished Equipment"

A key challenge in the pharmaceutical manufacturing and processing equipment market is the rising demand for refurbished machinery. More than 38% of small and medium-sized pharma companies prefer refurbished equipment due to lower upfront costs. The share of refurbished machinery in the market has grown by 29% year-on-year. This trend is particularly strong in developing economies, where over 44% of pharma startups opt for second-hand machines. Additionally, the long lifespan of pharmaceutical equipment—lasting more than a decade in 70% of cases—reduces replacement frequency. These factors together hinder the sales and innovation of new pharmaceutical processing equipment.

OPPORTUNITY

"Growth in Personalized Medicines"

The rise of personalized medicine is creating significant growth opportunities in the pharmaceutical manufacturing and processing equipment market. Over 52% of new drug approvals are now classified under personalized or targeted therapies. The need for small-batch, flexible, and highly controlled processing equipment has increased by 48% in the last three years. More than 46% of biotech firms producing cell and gene therapies are investing in adaptable, single-use processing lines. Additionally, 55% of pharmaceutical R&D investments are focused on niche disease areas, boosting demand for compact, configurable equipment. This shift is reshaping how manufacturing equipment is designed and used in the pharmaceutical sector.

CHALLENGE

" Rising Costs and Expenditures Related to Equipment Usage "

The pharmaceutical manufacturing and processing equipment market faces mounting challenges due to rising operational costs. Equipment maintenance and validation contribute to over 24% of total production expenses annually. Nearly 61% of pharma manufacturers report increased energy costs due to high-consumption processing machinery. Around 42% of companies struggle with skilled labor shortages to manage complex automation systems. Additionally, 37% of firms cite frequent software upgrades and digital system integration as cost burdens. Regulatory validation cycles extend equipment downtime by 28% on average, reducing productivity. These cumulative cost pressures are limiting adoption rates, especially among small and mid-sized pharmaceutical companies.

Segmentation Analysis

The Pharmaceutical Manufacturing and Processing Equipment market is segmented into types and applications. By type, dryers, granulators, and coaters make up 48% of the total equipment usage. Metal detectors and sifters together contribute 30%, while agitators, blowers, and others form 22%. In application terms, tablet production leads with 42% share, injectables account for 26%, and capsules hold 18%. Sprays, powders, and others make up the remaining 14%. Over 63% of pharma companies globally use multiple types of equipment depending on the formulation, and 57% prioritize modular systems for multi-application compatibility in pharmaceutical processing operations.

By Type

• Agitators: Agitators account for 9% of total equipment usage in pharmaceutical manufacturing. Over 61% of liquid and semi-solid production units utilize agitators. Among them, 44% have adopted high-shear agitators. Usage is rising due to increasing demand for emulsified and suspension-based formulations. About 53% of facilities require agitators for homogenization in pre-formulation stages.
• Blowers: Blowers contribute to 12% of pharmaceutical equipment installations. Around 58% of cleanroom environments depend on pharmaceutical-grade blowers for air handling. Demand for energy-efficient blowers increased by 31% in the last 3 years. 39% of manufacturing facilities have upgraded to low-noise, high-efficiency blower systems.
• Coaters: Coating machines represent 18% of global pharma equipment usage. Film-coating applications make up 65% of that usage, while sugar-coating accounts for 23%. The demand for controlled-release coatings grew by 33% in 5 years. Over 54% of solid-dose manufacturers rely on advanced coaters for batch consistency.
• Dryers: Dryers occupy 21% of the total installed pharmaceutical equipment base. Fluid bed dryers represent 61% of dryer usage. 47% of facilities using dryers prioritize quick-cycle drying. Vacuum dryers grew in usage by 28% due to demand for low-heat drying of heat-sensitive APIs.
• Granulators: Granulators make up 24% of total pharmaceutical manufacturing equipment. High-shear granulators dominate with 66% market share in this segment. 51% of tablet manufacturers use granulators for improved compressibility. Demand for wet granulation systems increased by 29% in the last 4 years.
• Metal Detectors: Metal detectors account for 14% of pharmaceutical equipment. Over 73% of tablet production lines include inline metal detection. Demand surged 38% due to increased global regulatory inspections. 62% of facilities upgraded their detection sensitivity in the past 5 years.
• Sifters: Sifters comprise 16% of total installations in powder and solid formulation plants. 68% of dry powder processing units use vibro sifters. 34% of sifter installations are for particle size optimization in inhalable formulations. Demand for fine-mesh sifters grew by 22%.
• Others: “Others” category, including mixers, tablet presses, and mills, contributes 26% to overall pharmaceutical manufacturing equipment usage. Multi-functional equipment saw a 31% growth in demand. 59% of pharmaceutical plants now use integrated systems under this category for increased production flexibility.

By Application

• Tablets: The tablet application holds the largest share of the pharmaceutical manufacturing and processing equipment market, accounting for 42% of total demand. Tablets are the most commonly produced solid dosage form, with increasing production volumes in both generic and branded drugs. The rise in chronic disease management and the aging population has fueled the demand for tablets. Over 58% of tablet production lines now employ high-speed tablet presses and automated coating systems to meet growing demand. Additionally, the shift towards controlled-release formulations has spurred the adoption of advanced tablet coating equipment, accounting for 29% of the total demand in tablet manufacturing.
• Capsules: Capsules represent 18% of the global pharmaceutical manufacturing equipment market. The growing preference for soft-gel capsules, particularly in the nutraceutical and supplement sectors, has led to a 39% increase in capsule-related equipment demand. Advances in capsule filling machines, which now offer higher precision and faster filling speeds, have boosted production efficiency. Over 66% of capsule production lines utilize automated systems for faster changeovers and reduced downtime. The demand for personalized medicine is also contributing to the rise in capsule production, with 33% of the global capsule equipment market focused on smaller, high-precision capsule systems.
• Injectable: Injectables hold 26% of the pharmaceutical manufacturing and processing equipment market, driven by the increasing need for vaccines, biologics, and parenteral drug delivery systems. The demand for aseptic processing equipment has surged by 39%, as more injectable products, particularly vaccines and biologics, require sterile environments. The shift towards pre-filled syringes and auto-injectors has also influenced equipment manufacturers, with 41% of injectable drug production lines now incorporating automated filling and sealing machines. The increasing trend toward biologics and gene therapies is expected to further increase demand for advanced injectable production equipment, with the segment growing steadily.
• Sprays: Sprays represent 6% of the pharmaceutical manufacturing and processing equipment market, mainly driven by nasal sprays and inhalable drugs. The demand for respiratory treatments, particularly in the treatment of asthma, COPD, and allergy medications, has led to a 23% increase in equipment usage for spray production. Pulmonary drug delivery systems require highly specialized equipment for precise dosing and sterilization, with 39% of spray production lines incorporating high-efficiency nozzles and metered-dose inhaler (MDI) systems. As personalized inhalable drug formulations increase, the market for spray production equipment is expected to grow by 15% over the next few years.
• Powders: Powder-based formulations make up 5% of the pharmaceutical manufacturing and processing equipment market, with a significant demand for inhaled powders, particularly for respiratory therapies. The equipment required for powder processing, including fluid bed dryers and vibro sifters, has seen a rise of 19% due to the increasing popularity of dry powder inhalers (DPIs). Powder production for capsule filling, as well as formulations for pediatric and geriatric drugs, also drives the market. Around 68% of powder production lines utilize granulation systems to ensure consistency and uniformity in the final product, contributing to the growth of powder processing equipment.
• Other: The “Other” application category, which includes drug forms like transdermal patches, lozenges, and suppositories, represents 3% of the pharmaceutical manufacturing and processing equipment market. The market for transdermal systems has grown by 17%, driven by advances in controlled drug release technology. The increasing demand for specialty dosage forms, including novel formulations for localized drug delivery, is contributing to the rise in equipment used in this segment. Furthermore, 31% of pharmaceutical facilities have adopted multi-functional equipment for the production of non-traditional dosage forms, reflecting a shift towards customization in pharmaceutical manufacturing processes.



Request a Free sample    to learn more about this report.

Regional Outlook 

Regionally, the Pharmaceutical Manufacturing and Processing Equipment market is divided among North America (34%), Europe (29%), Asia-Pacific (28%), and Middle East & Africa (9%). North America leads with 72% of regional pharma plants adopting automation. In Europe, 68% of companies use EMA-compliant equipment. Asia-Pacific shows rapid growth with 58% of new facilities established since 2020. Middle East & Africa equipment usage grew by 33% due to local manufacturing expansion. Global pharmaceutical investment in modern machinery increased by 47%, with regional governments supporting local production through incentives and regulatory simplification.

North America 

North America commands 34% of the pharmaceutical manufacturing and processing equipment market. Over 64% of facilities in the U.S. have transitioned to fully automated lines. Aseptic equipment demand grew by 41% in 3 years due to biologic product expansion. 38% of companies adopted continuous manufacturing technology. 76% of firms in the region use cGMP-compliant systems. Equipment replacement cycles are speeding up, with 33% of facilities replacing legacy systems with smart tech solutions. 49% of installations now include remote monitoring or AI-driven diagnostics to ensure compliance and boost productivity.

Europe

Europe accounts for 29% of the global pharmaceutical equipment market. Germany, France, and Italy collectively represent 61% of this share. Modular equipment adoption increased by 45%, and 36% growth was recorded in cleanroom technology installations. Over 57% of biologics manufacturers in Europe adopted single-use systems. EMA regulations influenced 68% of pharmaceutical firms to upgrade outdated systems. Energy-efficient equipment is now used by 42% of regional facilities. 52% of new installations include digital validation systems for audit readiness and batch control, reflecting increasing regulatory stringency in European production hubs.

Asia-Pacific

Asia-Pacific holds 28% of the pharmaceutical manufacturing and processing equipment market. China and India dominate with 69% of total regional installations. Generic drug production increased by 51%, driving equipment demand. 44% rise in biologics-related equipment was observed. 58% of new facilities use integrated lines for tablets and injectables. The region experienced a 39% growth in machinery investments due to government incentives. 65% of companies in Asia-Pacific deploy semi-automated systems to balance cost and productivity. 33% of installations now include data integration tools to align with global compliance norms.

Middle East & Africa 

Middle East & Africa contributes 9% to the pharmaceutical manufacturing and processing equipment market. UAE and South Africa represent 56% of the regional market. Pharmaceutical facility count increased by 33% post-2020. Vaccine manufacturing facilities grew by 42%, boosting sterile equipment installations. 64% of processing equipment is imported from Europe and Asia. 29% of new manufacturing projects rely on government or foreign investment. About 36% of companies are upgrading manual systems to basic automation. 41% of installations in Africa now follow WHO pre-qualification compliance, enhancing quality assurance standards.

LIST OF KEY Pharmaceutical Manufacturing and Processing Equipment Market COMPANIES PROFILED

• GEA
• Gericke
• Bohle
• Shimadzu
• Bausch+Stroebel
• Bosch
• ACG
• Truking
• ROMACO Group
• IMA
• Shinwa
• Chinasun
• Sartorius
• Tofflon

Top 2 Companies with Highest Market Share

• GEA – 13% global market share
• IMA – 11% global market share

Investment Analysis and Opportunities

The pharmaceutical manufacturing and processing equipment market is witnessing significant investments across various segments. Over 64% of global pharmaceutical companies have increased their spending on modernizing their manufacturing equipment in 2023 and 2024. 49% of these investments are specifically directed towards automated and digital systems. In Asia-Pacific, 43% of investments are focused on increasing production capacity, particularly in countries like India and China, which represent the largest share of pharmaceutical manufacturing.

The demand for sterile and aseptic equipment has led to a 39% rise in investment in this sector, driven by the increased production of biologics and vaccines. Modular and flexible manufacturing systems have also seen an increase in demand, with 47% of contract manufacturers investing in these systems. Moreover, the focus on energy-efficient technologies has led to 33% of global investments being allocated to sustainable equipment solutions. In North America, 52% of pharmaceutical companies are investing in advanced manufacturing technologies to meet strict FDA compliance and enhance production speed. The growth of the pharmaceutical sector in emerging markets is providing 26% of the global investment in equipment, particularly in Africa and the Middle East, where local production is rapidly expanding.

As 59% of global pharmaceutical companies are expected to increase their capital expenditures on equipment in the next 3 years, opportunities continue to emerge in high-tech solutions, energy-efficient systems, and automation technologies.

New Product Development

New product development in the pharmaceutical manufacturing and processing equipment market is primarily driven by the need for automation, regulatory compliance, and improved efficiency. In 2023 and 2024, over 41% of new products launched in the market featured integrated digital control systems for enhanced monitoring and optimization. Around 34% of product innovations focused on single-use systems, designed to address the growing demand for biologics manufacturing, especially in sterile environments.

High-shear granulators and mixers represented 28% of new products introduced, with several models offering faster batch processing and inline monitoring capabilities. Coating systems with real-time spray rate adjustment and humidity control saw a 52% increase in product development, driven by demand for controlled-release drug formulations. Fluid bed dryers introduced in 2024 are 46% more energy-efficient than previous models, reflecting the industry’s push toward sustainability.

Furthermore, over 61% of newly launched pharmaceutical manufacturing equipment includes cloud-based analytics, offering real-time data access for better decision-making. Robotic capsule filling systems have gained traction, with 39% of new product lines incorporating features like auto-calibration for faster and more accurate operations. In Asia-Pacific, 48% of new products are compact, multi-functional models, catering to smaller pharmaceutical production facilities. In Europe, 36% of new equipment releases emphasize eco-friendly features, reducing energy consumption by 22% compared to previous versions.

Recent Developments by Manufacturers in 2023 and 2024 

The pharmaceutical manufacturing and processing equipment market has seen several key developments by manufacturers in 2023 and 2024, reshaping the industry landscape:

• GEA launched a continuous granulation system with 37% faster throughput in Q2 2023, targeting large-scale solid dosage production.
• IMA implemented IoT technology in 43% of its product lines by Q3 2024, enabling predictive maintenance and remote diagnostics for pharmaceutical companies.
• ACG expanded its manufacturing capacity by 28% in India, aiming to meet the increasing global demand for capsule filling machines.
• Tofflon collaborated with a biotech company in early 2024 to develop a high-speed lyophilization system, improving drying time by 35%.
• Bausch+Stroebel introduced a robotic vial inspection system in 2023, achieving 62% higher defect detection accuracy compared to manual systems.
• Sartorius integrated cloud-based analytics into 57% of its bioprocessing systems for real-time monitoring of critical parameters in drug production.
• Bosch Packaging developed modular systems that reduce setup time by 48%, accelerating production for injectable drugs.

Additionally, 51% of manufacturers reported increasing their R&D investments in 2023, focusing on the development of flexible, high-output equipment. These developments are shaping the future of the pharmaceutical manufacturing sector, fostering growth in automation and digitalization.

Report Coverage

The pharmaceutical manufacturing and processing equipment market report provides a comprehensive overview of the market dynamics, trends, and key developments across different regions. It covers over 92% of the equipment types currently in demand across pharmaceutical production lines globally, offering insights into 15+ key segments including agitators, blowers, coaters, and granulators. The report analyzes the competitive landscape, with detailed profiles of 100+ equipment manufacturers and their market shares.

78% of the data included in the report is sourced from primary industry interviews, OEM surveys, and direct facility audits. It includes analysis on 60% of the global product portfolios from key players, providing insights into product development trends, market strategies, and innovation pipelines. The report also evaluates 360-degree market perspectives, including investment strategies, technological advancements, and sustainability trends, which have become crucial drivers in the pharmaceutical manufacturing sector.

The regional outlook covers North America, Europe, Asia-Pacific, and the Middle East & Africa, accounting for 100% of the global pharmaceutical production capacity. Over 80% of the report focuses on emerging trends such as digitalization, automation, and regulatory compliance, with a particular emphasis on Industry 4.0 applications. Additionally, it provides forecasts for market growth, equipment lifecycle analysis, and insights into 33% of top-performing pharmaceutical manufacturing companies worldwide.